Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the ...

Too many copies of the HER2 gene or its overexpression appeared to cause an especially aggressive form of the disease. By the late ’90s, a drug called Herceptin that targeted the HER2 receptor, sped ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Many experts are frustrated and troubled by the state of HER2 testing, especially as new opportunities for tests are on the horizon. And as trials testing Herceptin at earlier stages and in ...

In HER2-positive early breast cancer, Kadcyla shows sustained improvement in both invasive disease-free survival and overall survival versus Herceptin.

Phesgo combines the anti-HER2 antibodies in Herceptin (trastuzumab) and Perjeta (pertuzumab) in a subcutaneous injection that takes a few minutes to deliver. At the moment, Herceptin is available ...

Some cancers, instead, have particularly high levels of a protein called HER2. The drug Herceptin, a monoclonal antibody, attacks this protein and effectively fights the cancer. Herceptin has ...

The observational study measured how physicians changed treatment plans after seeing HER2DX results and how patients did on the new plans.

Phesgo comes in a single-dose vial and can be dosed as a subcutaneous injection, while at the moment breast cancer patients the two anti-HER2 drugs separately receive Herceptin as a subcutaneous ...

Shares of Puma Biotechnology PBYI have rallied 35.3% in the past six months against the industry’s decline of 9.2%. The ...

They are widely used for: HER2-Positive Breast Cancer: The most common indication for Herceptin biosimilars, improving survival rates in breast cancer patients. HER2-Positive Gastric Cancer ...